Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propoxycaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 6/20 | 0.98 |
| ▸ | SCN2A known ✓ | Q99250 | 6/20 | 0.98 |
| ▸ | SCN3A known ✓ | Q9NY46 | 6/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.66 |
| ▸ | HTR3A | P46098 | 3/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propoxycaine SCHEMBL83073 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL29353209 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL1651061 | 0.96 | SCN1A (0.95) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL1007224 | 0.95 | CYP2D6 (0.88) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL82280 | 0.94 | SCN1A (0.91) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL8683800 | 0.90 | CYP1A2 (0.83) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL14304166 | 0.88 | CYP1A2 (0.80) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL22987103 | 0.87 | CYP1A2 (0.78) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL5925620 | 0.86 | CYP2D6 (0.77) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL3660746 | 0.86 | SCN1A (0.76) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 761 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691283-B2 | Standardized bee venom preparation | KIM CHRISTOPHER M (KR) | 2014-04-08 | — | — | US | claimed |
| US-20130216517-A1 | STANDARDIZED BEE VENOM PREPARATION | KIM CHRISTOPHER M (KR) | 2013-08-22 | — | — | US | claimed |
| US-8440234-B2 | Standardized bee venom preparation suitable for administration by injection comprising; Bee venom treatment without the sting | KIM CHRISTOPHER M (KR) | 2013-05-14 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100003322-A1 | ENTERIC COATED HYDROPHOBIC MATRIX FORMULATION | IMPAX LABORATORIES, INC. | 2010-01-07 | — | — | US | claimed |
| US-20070141096-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. | 2007-06-21 | — | — | US | claimed |
| EP-0615749-B1 | Use of NMDA antagonists for the treatment of pain | UNIV VIRGINIA COMMONWEALTH (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20020044968-A1 | High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion | GENERAL MILLS, INC. | 2002-04-18 | — | — | US | claimed |
| JP-2002511777-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1119345-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0643964-A2 | Use of local anesthetics for the manufacture of a medicament for the protection of plasma cell membranes | Medipharma S.A. (AR) | 1995-03-22 | — | — | EP | claimed |